ACAD has done a great job here. As the company have previously said, they only have to repeat P2 trial. This is best outcome for all. The drug gets to those who need it quicker.
The trial will be enrolled quickly. Parents will be lining up to get started.
Becoming a really strong buy now.
- Forums
- ASX - By Stock
- Ann: Plans for Phase 3 trial in Rett syndrome
ACAD has done a great job here. As the company have previously...
-
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.55 |
Change
0.690(3.47%) |
Mkt cap ! $2.583B |
Open | High | Low | Value | Volume |
$20.00 | $20.66 | $19.94 | $4.017M | 197.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 31 | $20.54 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.55 | 1 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 85 | 20.550 |
3 | 75 | 20.540 |
7 | 342 | 20.530 |
7 | 350 | 20.520 |
5 | 345 | 20.510 |
Price($) | Vol. | No. |
---|---|---|
20.570 | 295 | 5 |
20.580 | 167 | 2 |
20.590 | 163 | 2 |
20.600 | 1220 | 4 |
20.610 | 434 | 5 |
Last trade - 13.45pm 12/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |